News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
Major Finding: The number of new surgically eligible basal cell carcinomas was 0.07/month in patients receiving active treatment with vismodegib v...
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
Major Finding: The number of new surgically eligible basal cell carcinomas was 0.07/month in patients receiving active treatment with vismodegib v...
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
Major Finding: Disease control at 8 weeks was 83% in patients with one signature vs. 0% in those without it, and 64% vs.
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
Major Finding: Disease control at 8 weeks was 83% in patients with one signature vs. 0% in those without it, and 64% vs.
News
- Author:
- Sharon Worcester
Publish date: April 4, 2011
Major Finding: Disease control at 8 weeks was 83% in patients with one signature vs. 0% in those without it, and 64% vs.
News
- Author:
- Sharon Worcester
Publish date: April 1, 2011
News
- Author:
- Sharon Worcester
Publish date: April 1, 2011
News
- Author:
- Sharon Worcester
Publish date: April 1, 2011
News
- Author:
- Sharon Worcester
Publish date: April 1, 2011
News
- Author:
- Sharon Worcester
Publish date: March 31, 2011
Major Finding: ADHD-IV Rating Scale scores were reduced significantly more in the treatment vs. placebo groups, based on both parent reports ...
News
- Author:
- Sharon Worcester
Publish date: March 31, 2011
Major Finding: ADHD-IV Rating Scale scores were reduced significantly more in the treatment vs. placebo groups, based on both parent reports ...